vTv Therapeutics (VTVT) Amortization of Deferred Charges (2015)

vTv Therapeutics (VTVT) reported Amortization of Deferred Charges of $13000.0 for Q2 2015, down 7.14% sequentially from $14000.0 in Q1 2015.

vTv Therapeutics (VTVT) Amortization of Deferred Charges (2015) Analysis & Trends

vTv Therapeutics (VTVT) has 1 years of Amortization of Deferred Charges data on file, last reported at $13000.0 in Q2 2015.

For the quarter ending Q2 2015, Amortization of Deferred Charges changed N/A year-over-year to $13000.0; the trailing twelve-month figure through Dec 2015 stood at $27000.0 (changed N/A YoY), and the FY2015 full-year result was $27000.0, down 81.38% from the prior year.
Amortization of Deferred Charges declined to $13000.0 in Q2 2015, from $14000.0 in the prior quarter.
In the past five years, Amortization of Deferred Charges ranged from a high of $14000.0 in Q1 2015 to a low of $13000.0 in Q2 2015.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)
1	Oculis Holding AG	66,621.14 Bn	66,620.85 Bn	-
2	Nanobiotix	1,915.18 Bn	1,915.11 Bn	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-
4	BeOne Medicines	471.27 Bn	466.48 Bn	1.35 Bn
5	Vertex Pharmaceuticals	121.81 Bn	114.57 Bn	2.59 Bn
6	Regeneron Pharmaceuticals	69.58 Bn	60.82 Bn	3.31 Bn
7	Belite Bio	62.72 Bn	62.72 Bn	-
8	Argenx Se	55.51 Bn	50.33 Bn	1.41 Bn
9	Revolution Medicines	37.35 Bn	37.35 Bn	-
10	vTv Therapeutics	19.21 Mn	19.21 Mn	-

Download Data